Quick Answer
Xenon Pharmaceuticals Inc. reported Stockholders Equity of $581.76 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -22.9% in Stockholders Equity from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$67.51 million | Q1 2015: $68.97 million | Q2 2015: $64.35 million | Q3 2015: $64.46 million | Q1 2016: $58.16 million | Q2 2016: $52.66 million | Q3 2016: $69.31 million | Q1 2017: $57.20 million | Q2 2017: $50.45 million | Q3 2017: $43.30 million | Q1 2018: $28.50 million | Q2 2018: $50.62 million | Q3 2018: $111.16 million | Q1 2019: $92.31 million | Q2 2019: $82.79 million | Q3 2019: $74.56 million | Q1 2020: $187.98 million | Q2 2020: $189.30 million | Q3 2020: $182.02 million | Q1 2021: $276.28 million | Q2 2021: $256.98 million | Q3 2021: $248.94 million | Q1 2022: $541.85 million | Q2 2022: $785.79 million | Q3 2022: $753.12 million | Q1 2023: $686.94 million | Q2 2023: $646.46 million | Q3 2023: $636.59 million | Q1 2024: $887.70 million | Q2 2024: $844.05 million | Q3 2024: $797.81 million | Q1 2025: $703.96 million | Q2 2025: $633.98 million | Q3 2025: $559.51 million.
- Over the full 15 years of available data (2011 to 2025), Xenon Pharmaceuticals Inc.'s Stockholders Equity has grown by 774.0%.
- Historical annual values: Fiscal year 2025: $581.76 million | Fiscal year 2024: $754.90 million | Fiscal year 2023: $927.92 million | Fiscal year 2022: $721.50 million | Fiscal year 2021: $550.03 million | Fiscal year 2020: $171.36 million | Fiscal year 2019: $91.98 million | Fiscal year 2018: $103.30 million | Fiscal year 2017: $35.93 million | Fiscal year 2016: $63.90 million | Fiscal year 2015: $61.03 million | Fiscal year 2014: $72.78 million | Fiscal year 2013: -$78.37 million | Fiscal year 2012: -$89.87 million | Fiscal year 2011: -$86.32 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: